Dr. Vishnu N. Badavath

Assistant Professor

Experience: 7 years

Introduction

Professional experience:

Research experience: 12 yrs.

Teaching: 2 yrs

Industrial experience: 1.5yrs

Postdoctoral Research experience: 3.5yrs

Area of Research Interest:   

My research focuses on the interdisciplinary area between molecular biology and organic chemistry (organic, medicinal, and carbohydrate) design, synthesis, and screening of novel synthetic and natural based compounds for the treatment of viral infections, i.e., (SARS-CoV-2, Dengue, Chikungunya, and Enterovirus). and the designing of a novel for the treatment of various diseases (cancer, Diabetes, and other central nervous system-related diseases

• Organic/Medicinal/Carbohydrate/Natural products chemistry 
• CADD- Computer-Aided Drug Design 
• Molecular Biology and Chemical Biology 
• Activity based probes attach nanoparticles to determine the minimal tumour size detected by CT-Probes. 

Technology developed:

1. Identified and isolates two new strains of N. gonorrhoeae (NG-083 and NG-091) from urethral swab in male heterosexual patients from Thai Red Cross Anonymous Clinic, The corresponding genome sequence of N. gonorrhoeae reference strain FA1090 (GenBank accession number AE004969) Mosaic XXXIV, and new mosaic pattern (GC-013) were compared with the wild type PBP2 of N. gonorrhoeae strain LM306 (GenBank accession no. AAA25463). Scientific Reports 11.1 (2021): 21659. https://doi.org/10.1038/s41598-021-00675-y
2. Designed & developed continuous flow photo-reactor for polysaccharide synthesis. Special Issue on "Synthetic Carbohydrate Chemistry. Indian Chem. Soc., Vol. 97, February 2020, pp. 227-236.
3. Field of Study: Antibacterial Resistance, Objective: To overcome the pneumonia infection caused by Klebsiella pneumoniae for the first time we found that Ca-EDTA restores the activity of ceftazidime-avibactam  or aztreonam against carbapenemase-producing Klebsiella pneumoniae infections. Iscience7 (2023): 107215. https://doi.org/10.1016/j.isci.2023.107215

 Postdoctoral Research experience:

1. Postdoctoral Research Fellow, Institute for Drug Research, The Hebrew University of Jerusalem, Israel. 2019 to Mar. 2021:
2. Postdoctoral Research Fellow, Faculty of Medicine, Chulalongkorn University, Thailand. ( 2018 to Aug. 2019).
3. Postdoctoral Research Fellow, of Chemistry, Indian Institute of Technology, Banaras Hindu University (IIT-BHU). Varanasi, India. (Sep. 2017 to Jul. 2017).
4. Worked as Project Research assistant, under the supervision of T. Narender, Principal Scientist, MPC-Division, Central Drug Research Institute CDRI-Lucknow, India. (Jun. 2010 to 2011).

Industrial Experience:

1. Worked as Research Associate in Synthetic Research & Development, Reddy’s ILS, Hyderabad (Jun. 2016 to Aug. 2017).
2. Worked as Senior Chemist in pilot plant R & D, at Brundavan Lab. Pvt. Ltd. (Apr. 2016 to Jun. 2016).

Teaching experience:

1. Worked as Assistant Professor, Chitkara College of Pharmacy, Chitkara University, Punjab (From Apr. 2021 to Apr. 2022)
2. Currently working as Assistant Professor, SVKM’s NMIMS University (Narsee Monjee Institute of Management Studies) University (May. 2022 to till date)

Awarded Scholarship/Fellowships:

1. Recipient of prestigious Rachadapisaek Sompot Fund from Graduate School, Chulalongkorn University, Bangkok, Thailand. (Period: 1^st 2018 to 31^st June 2019).
2. Received Indo-Max Planck Project Fellow (R&D/DST/Max-Planck/MoU/LT/Che/16-17/04/part/02). from Dept. of Chemistry, Indian Institute of Technology, Banaras Hindu University. Varanasi, India.
3. CSIR-UGC-NET-June 2016, in Chemical Sciences with AIR 79 rank.
4. GATE-2009, with72 percentile, conducted by Indian Institute of Technology (IIT), Roorkee, India.
5. NIPER-JEE-2009. Conducted by NIPER-Mohali, India. (Recipient of Postgraduate Fellow from Ministry of Chemicals & Fertilizers, Govt. of India (2009- 2011).
6. GPAT-2015-Conducted by All India Council for Technical Education (AICTE), New Delhi, G of India.
7. Birla Institute Fellowship Award 2011-14 9 (Ph. D Entrance Exam-2011) for Pursuing D from Birla Institute of Technology (BIT)-Mesra, Ranchi, India. (Period: Sep. 2011 to Sep. 2014).
8. Post Matric Fellowship (EAMCET-2005/ renamed as NEET) from Higher Technical Education, of Andhra Pradesh, 2005-2009 for pursuing B. Pharmacy from Osmania University Hyderabad, Andhra Pradesh, India 

Research and Publications:

2023

1. Wannigama DL, Shein AM, Hurst C, Monk PN, Hongsing P, Phattharapornjaroen P, Ditcham WG, Ounjai P, Saethang T, Chantaravisoot N, Wapeesittipan P, Vishnu Nayak Badavath, et al., Ca-EDTA restores the activity of Ceftazidime-Avibactam or Aztreonam against carbapenemase-producing Klebsiella pneumoniae infections. iScience (Cell Press) 2023, 28:107215. (https://doi.org/10.1016/j.isci.2023.107215). (IF: 6.23, Q1).
2. Saurabh Gupta, Ajmer Singh Grewal, Geeta Deswal, Sachin Singh, Sukrati Vishwas, Vishnu Badavath, Kamal Dua, Priyanka Thakur, Thakur Gurjeet Singh. In Silico Docking Studies of Yucca gloriosa L. Phytoconstituents with TNF-α, IL-6 and IL-13 Receptor Against Asthma. Chemical Biology Letters -ScienceIn. 2023 (Just accepted). (IF: 1.27, Q2).
3. Sudhakar; M. Saravanabhavan; RAMESH K S; Shabbir Muhammad; Saifeldin M. Siddeeg; Vishnu Nayak Badavath; S. Chandrasekar; M Sekar. Crystal Growth, Optoelectronic and Biological Properties of Acetamidinium Compounds: Experimental and Computational Approaches. Journal of Materials Science: Materials in Electronics (JMSE). 2023, Just accepted (IF: 2.77, Q2).

2022

4. Abhishek T^#, Gaurav S^#, Vishnu Nayak Badavath^#, Venkatesan J, Kenneth M. Merz, Jr., Galia Blum*, Orlando Acevedo. Primer for Designing Main Protease (M^pro) Inhibitors of SARS-CoV‑2. ACS-J. Phys. Chem. Lett. 13, 5776-5786. (IF: 6.88). doi.org/10.1021/acs.jpclett.2c01193.
5. Sukrit S, D. L. W, Paul G. H, Cameron H, Chanikan T, Pattama W, Phatthranit P, Vishnu N. Badavath, Asada L, Tanittha Chatsuwan. Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin-sulbactam combination therapy. Nature-Scientific Reports. 2022, 12:11390. (https://doi.org/10.1038/s41598-022-15386-1) (IF: 5.31).
6. High prevalence of mgrB-mediated colistin resistance among carbapenem-resistant Klebsiella pneumoniae is associated with biofilm formation and can be overcome by colistin-EDTA combination therapy. Nature-Scientific Reports 2022, 12(1), 1-19. doi.org/10.1038/s41598-022-17083-5
7. Bhavya K, M. Manohar, R. Soumyajit, L. Arora, Vishnu Nayak Badavath, Madhu. S.R G.R, Suman D, Rambabu G, Novel imidazo[1,2-a]pyridine derivatives induce apoptosis and cell cycle arrest in non-small cell lung cancer by activating NADPH oxidase mediated oxidative stress. Life Science. 2022, 294, 120334. (IF: 6.78).
8. Vishnu Nayak Badavath, Abhishek Thakur, Deepak Shilkar, Chandrani Nath, Orlando Acevedo, Gulberk Ucar, Venkatesan Jayaprakash. Brain permeable curcumin-based pyrazoline analogs: MAO inhibitory and antioxidant activity. Mol. Struct. 2022, 1268, 133681. doi.org/10.1016/j.molstruc.2022.133681.

9. Effectiveness of Chinese herbal medicine Zhi Shi Xiao Pi Wan on adult diabetic gastroparesis: a systematic review and meta-analysis. F1000Research 2022, 11:861 (29 Jul 2022, 11:861 (IF: 2.29). https://doi.org/10.12688/f1000research.123523.1)
10. Madhu R.G.R^#, Badavath VN^#, Velez C, Loeanurit N, Thakur A, Maddipati VC, Katari NK, Acevedo O, Boonyasuppayakorn S, Gundla R. Discovery of 3-chlorobenzyl linked 1, 9-diazaspiro [5.5] undecane derivatives, a lead for Dengue virus type 2 infection. RSC- New J. Chem., 2022, 46, 1087–1098. (IF: 3.59).
11. Chidvilas Kurapati, Kalyani Paidikondala, Vishnu Nayak Badavath, Om V. Singh, Rambabu Gundla Design, and synthesis of N-benzyl Spiro-piperidine hydroxamic acid-based derivatives: HDAC inhibitory activity and drug-likeness prediction. Journal of Heterocyclic Chemistry. 11 (2022): 2006-2015. (DOI: 10.1002/jhet.4538) (IF: 2.03).
12. Purna Koteswara Rao, Bhaskara Rao T, Kali Charan Gulipalli, Srinu Bodige, Vishnu Nayak Badavath, Gattu Sridhar, Kiran Gangarapu. Design and Synthesis of Novel Urea Derivatives of Pyrimidine-Pyrazoles as Anticancer Agents. J. Mol. Struct., 2022, 1251, 131937. (IF: 3.81).
13. Tapan Behl, Sachin Kumar, Ziyad M Althafar, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Vishnu Nayak Badavath, Shivam Yadav, Saurabh Bhatia, Ahmed Al-Harrasi, Yosif Almoshari, Mohannad A Almikhlafi, Simona Bungau. Exploring the Role of Ubiquitin–Proteasome System in Parkinson's Disease. Molecular Neurobiology, 2022, 59, 4257–4273 (DOI: 1007/s12035-022-02851-1 ). (IF: 5.68).
14. Sudhakar, M. Saravanabhavan, K.S.Ramesh, V.N.Badavath, S.Chandrasekar, B.Babu, M. Sekar. Pharmacological and Quantum Chemical Studies of 2-aminobenzo[d]thiazol-3-ium 4-chlorobenzenesulphonate: Synthesis, Spectral, Thermal Analysis and Structural Elucidation. Results in Chemistry. 2022, 100442. https://doi.org/10.1016/j.rechem.2022.100442
15. Tapan Behl, Amit Gupta, Sridevi Chigurupati, Sukhbir Singh, Aayush Sehgal, Vishnu Nayak Badavath, Ahmad Alhowail, Vasudevan Mani, Saurabh Bhatia, Ahmed Al-Harrasi, Simona Bungau. Natural and Synthetic Agents Targeting Reactive Carbonyl Species against Metabolic Syndrome. Molecules. 2022, 27, 1583. (IF 4.92).
16. Dapinder Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Vishnu Nayak Badavath, Mohammad Mehedi Hasan, Saurabh Bhatia, Ahmed Al-Harassi, Haroon Khan, Simona Bungau. Unravelling the Potential Neuroprotective Facets of Erythropoietin for the treatment of Alzheimer’s disease. Metabolic Brain Disease. 2022, 37, 1-16 (IF: 3.65).  https://doi.org/10.1007/s11011-021-00820-6
17. Rajesh Ghosh^#, Vishnu Nayak Badavath^#, Snehasis Chowdhuri, Anik Sen. Identification of Alkaloids from Terminalia chebula as Potent SARS-CoV-2 Main Protease Inhibitors: An In Silico Perspective. Chemistry Select, 2022, 7(14), (IF: 2.10). https://doi.org/10.1002/slct.202200055
18. Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora, Vishnu Nayak Badavath. Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry. 2022, Volume 23, Issue 1, 2023, 53-66 (Just accepted). DOI: 2174/1389557522666220524090354 (IF: 3.86).

 

2021

19. Kueakulpattana, N., Wannigama, D. L., Luk-In, S., Hongsing, P., Hurst, C., Vishnu Nayak Badavath, et al., Multidrug-resistant Neisseria gonorrhoeae infection in heterosexual men with reduced susceptibility to ceftriaxone, first report in Thailand. Nature-Scientific Reports,2021, 11(1), 1-16. (IF: 5.13).
20. Suresh^#, Vishnu Nayak Badavath^#, T. Abhishek^#, Na Yin^#, D. J. Steven, Orlando Acevedo, Dirk Jochmans, Pieter Leyssen, Ke Wang, Johan Neyts, Tao Yujie, Galia Blum*. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS- CoV-2, a Lead Compound for Blocking COVID-19. ACS-J. Phys. Chem. Lett. 2021, 12 (7), 1793–1802 (IF: 6.74).
21. Aita, S., Badavath, V.N., Gundluru, M., Sudileti, M., Nemallapudi, B.R., Gundala, S., Zyryanov, G.V., Chamarti, N.R. and Reddy, C.S., 2021. Novel α-Aminophosphonates of Imatinib Intermediate: Synthesis, Anticancer Activity, Human Abl Tyrosine Kinase Inhibition, ADME and Toxicity Prediction.  Chem., 2021, 109, 104718. (IF: 5.27).

22. Kaur, Dapinder, Tapan Behl, Sridevi Chigurupati, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Vishnu Nayak Badavath et al., Deciphering the focal role of endostatin in Alzheimer’s disease. Environmental Science & Pollution Research.2021, 28, 61998–62011 (IF: 4.22)
23. Alkyne-Tagged Apigenin, a Chemical Tool to Navigate Potential Targets of Flavonoid Anti-Dengue Leads. Molecule, 2021, 26 (22), 6967. (IF: 4.41).
24. Reddivari CK, Devineni SR, Nemallapudi BR, Sravya G, Avula B, Shaik N, Badavath VN, Zyryanov GV, Yellala Venkata RR, Chamarthi NR. Design, Synthesis, biological evaluation, and molecular docking studies of 1,4-disubstituted 1,2,3-triazoles: PEG-400: H₂O mediated Click reaction of fluorescent organic Probes under ultrasonic irradiation. Aromat. Compd. 2021, 1-22 (IF: 3.74).
25. Gangireddy MS, Mantipally M, Badavath VN, Maddipati VC, Paidikondala K, Katari NK, Gundla R. Design, synthesis, and molecular docking of piperidin-4-amine linked pyrimidine derivatives as potent anticancer agents. Data. Coll., 2021, 32, 100646. (IF: 2.21).

2020

26. Yasmin, S., Cerchia, C., Badavath, V.N., Laghezza, A, etal., A Series of Ferulic Acid Amides Reveals Unexpected Peroxiredoxin 1 Inhibitory Activity with in vivo Antidiabetic and Hypolipidemic Effects. 2020, 15, 1-16 (IF: 3.46).
27. Badavath, V.N., Kumar, A., Samanta, P.K., Maji, S., Das, A., Blum, G., Jha, A. and Sen, A. Determination of Potential Inhibitors based on Isatin derivatives against SARS-Cov-2 Main protease (M^pro): A Molecular Docking, Molecular dynamics and Structure-Activity Relationship Studies. Biomol. Struct. Dyn. 2020, 1-19 (IF: 3.31).
28. Gundluru M, Badavath VN, Shaik HY, Sudileti M, Nemallapudi BR, Gundala S, Zyryanov GV, Cirandur SR. Design, synthesis, cytotoxic evaluation and molecular docking studies of novel thiazolyl α-aminophosphonates. Chem. Intermediate.2021, 47,1139-1160 (IF: 2.91).
29. Ravi Jarapula, Vishnu N. Badavath, Shriram Rekulapally, Sarangapani M. Computational studies of bis-2-oxoindoline succinohydrazides and their in vitro Curr. Comput. Aided Drug Design,2020, 16(3), 270-280. (IF: 1.60).
30. Tiwari V, Badavath VN, Singh AK, Kandasamy Jeyakumar. Synthesis of photolabile group protected anomeric acetals and its application in carbohydrate synthesis with the assistance of continuous flow photo-reactor. Elsevier- Ind. Chem. Soc., 2020, 97, 227-236. (IF: 0.28).
31. S. Jadav, Vishnu Nayak Badavath*, Ramesh G, Narayana M. G, B. N. Sinha, Dominique Besson, Venkatesan J. Biological evaluation of 2-aminothiazole hybrid as antimalarial and antitrypanosomal agents: Design and synthesis. Anti-Infective Agents, 2020, 18(2), 101-108 (IF: 1.0).

2019

32. Saravanabhavan, M., Badavath, V.N*. Maji, S., Muhammad, S. M. Sekar. Novel halogenated pyrido[2,3-a]carbazole with enhanced aromaticity as potent anticancer and antioxidant: Rationale design and microwave assisted synthesis. RSC-New J. Chem. 2019, 43 (44), 17231-17240. 9 (IF: 3.59).
33. Mantipally, M., Gangireddy, M.R., Gundla, R., Badavath, V.N., Mandha, S.R. and Maddipati, V.C Rational design, molecular docking, and synthesis of novel homopiperazine linked imidazo[1,2 a]pyrimidine derivatives as potent cytotoxic and antimicrobial agents. Med. Chem. Lett. 2019.29 (16), 2248-2253. (IF: 2.82).

 

34. S. Reddy, J. Mao, L.S. Krishna, Badavath, V.N, Maji, S. Synthesis, Spectral investigation, molecular docking and biological evaluation of Cu(II), Ni(II) and Mn(II) complexes of (E)-2-((2-butyl-4-chloro-1H-imidazol-5-yl)methylene)-N-methylhydrazine carbothioamide (C₁₅H₁₈N₅ClS) and its DFT studies. J. Mol. Struct. 2019, 1196, 338-347 (IF. 3.19).
35. Reddy, A.S., Mao, J., Vanitha, S., Badavath, V.N., Krishna, L.S. and Lavanya, M. Synthesis, spectral characterization, molecular docking studies, biological activity of (E)-2-((E)-3-(3,4,5-trimethoxyphenyl)allylidene) and (E)-N-phenyl 2-((E)-3-(3,4,5-trimethoxyphenyl) allylidene) hydrazine carbothioamides and their Cu(II) complexes. Saudi. Chem. Soc. 2019, 23 (7), 947-957. (IF. 3.93).
36. Suba, V., G. Rathika, E. Ranjith K, M. Saravanabhavan, Vishnu Nayak Badavath, K. S. Thangamani., Enhanced Adsorption and Antimicrobial Activity of Fabricated Apocynaceae Leaf Waste Activated Carbon by Cobalt Ferrite Nanoparticles for Textile Effluent Treatment. Inorg. Organomet. Polym. 2019, 29(2), 550-563. (IF: 3.54).
37. Gangireddy, M.R., Mantipally, M., Gundla, R., Badavath, V.N., Paidikondala, K. and Yamala, A. Design and synthesis of piperazine linked imidazo[1,2-a]pyridine derivatives as potent anticancer agents. Chemistry Select, 2019, 4 (46), 13622-13629. ( 2.10).

2018

38. Varsha T, Vishnu Nayak Badavath, Adesh Kumar Singh, Jeyakumar Kandasamy. A highly efficient TEMPO-mediated oxidation of sugar primary alcohols into uronic acids using 1-chloro-1, 2-benziodoxol-3(1H)-one at room temperature. Tetrahedron Lett., 2018, 59, (26), 2511–2514 (IF: 2.41).
39. Chandrani N, Vishnu N. Badavath, Abhishek Thakur, Gulberk Ucar, Orlando Acevedo, M.U.M. Siddique, Venkatesan Jayaprakash. Curcumin-based pyrazoline analogues as selective inhibitors of human monoamine oxidase A. Chem. Commun., 2018, 9, 1164-1171. (IF: 3.35).

2017

40. Vishnu Nayak Badavath*, Chandrani Nath, Narayana M. Ganta, Gulberk Ucar, Barij N. Sinha, Venkatesan Jayaprakash. Design, synthesis, molecular docking and MAO inhibitory activity of 2-(arylmethylidene)-2,3-dihydro-1-benzofuran-3-one derivatives. Elsevier-Chinese Chemical Letters. 2017, 28 (7), 1528-1532. (IF: 6.77).

2016

41. Vishnu Nayak Badavath, Ipek Baysal, Gulberk Ucar, B. N. Sinha, Venkatesan Jayaprakash, Monoamine oxidase inhibitory activity of novel Pyrazoline analogues: Curcumin based design and synthesis, ACS-Med. Chem. Lett., 2016, 7, 56-61. (IF: 4.34).
42. Saravanabhavan, M., Badavath, V.N*. Maji, S., Muhammad, S. and Sekar, M Novel halogenated pyrido[2,3-a]carbazole with enhanced aromaticity as potent anticancer and antioxidant: Rationale design and microwave assisted synthesis. RSC-New J. Chem. 2019, 43 (44), 17231-17240. 9 ( 3.59).
43. Vishnu Nayak Badavath, G. Ucar, B. N. Sinha, S. Mondal, V. Jayaprakash. Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis-II. Chemistry Select, 2016, 1, 1-7. (IF: 2.10).

2015

44. Vishnu Nayak Badavath, S. C. Yabanoglu, S. Bhakat, K. Timiri, B.N. Sinha, G. Ucar, M. E.S. Soliman, V. Jayaprakash, Monoamine oxidase inhibitory activity of 2-aryl-4H- chromen-4-ones, Bioorg. Chem., 2015, 58, 72-80. (IF: 5.27).
45. S. Jadav, S. Kaptein, A. K. Timiri, Tine De B, Vishnu Nayak Badavath, Ramesh G, B. N. Sinha, Johan Neyts, Pieter Leyssen and Venkatesan J. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors. Bioorg. Med. Chem. Lett., 2015, 25, 1747-1752. (IF: 2.82). ISSN:0960-894X
46. Vishnu Nayak Badavath, Ipek Aysal, Gulberk Ucar, S. Mondal, B. N. Sinha, V. Jayaprakash, MAO inhibitory activity of Ferulic Acid Amides: Curcumin based design and synthesis, Wiley-Archiv der Pharmazie, 2015, 348, 1-11. (IF: 3.75). ISSN:1521-4184
47. Vishnu Nayak Badavath, I. Baysal, G. Ucar, B. N. Sinha, S. K. Mondal, Venkatesan Jayaprakash. Monoamine oxidase-A inhibitory activity of novel Curcumin analogues. Pharm. Chem., 2015, 2, 12-17. ISSN: 2349-5731(Online)
48. Vishnu Nayak Badavath, A. K. Singh, S. S Jadav, N. Mishra, D. Abhimanyu, B. N. Sinha, Venkatesan J. Pyrazoline carboxylates as selective MAO-B inhibitors: Synthesis and Biological screening. Pharm. Chem. 2015, 2, 1-5. ISSN: 2349-5731 (Online)
49. Vishnu Nayak Badavath*, B. N. Sinha, Venkatesan Jayaprakash, Design, in-silico docking and predictive ADME properties of novel Pyrazoline derivatives with selective human MAO inhibitory activity, J. Pharm. Pharm. Sci., 2015, 7, 277-282. ISSN: 0975-1491 Online, 2656-0097 Print
50. K. Timiri, Vishnu Nayak Badavath, B. N. Sinha, Venkatesan J, Subasri Selvarasu, Vishwanathan Vijayan, Velmurugan Devadasan. Synthesis, spectral and crystal studies of 2-(4, 6-diamino pyrimidin-2-ylthio)-N-m/p-tolyl/3, 4-dimethylacetamides. Formulation Development and Analysis. 2015, 1, 7-14.

2013

51. Vishnu Nayak, S. Ciftci-Yabanoglu, S. S. Jadav, Monika Jagrat, B. N. Sinha, G. Ucar, Venkatesan Jayaprakash, Monoamine oxidase inhibitory activity of 3, 5-biaryl-4, 5- dihydro-1H-pyrazole-1-carboxylate derivatives, Eur. J. Med. Chem., 2013, 69, 762-767. (IF: 6.51). ISSN: 0009-4374 (print); 0223-5234 (web)

2011

52. Narender, K. Venkateswarlu, B. Vishnu Nayak and S. Sarkar. A new chemical access for 3'- acetyl-4'-hydroxychalcones using BF₃-Et₂O via a regioselective Claisen-Schmidt condensationand its application in the synthesis of chalcone hybrids, Tetrahedron Letters, 2011, 52, 5794- 5798. (IF: 2.41). ISSN: 0040-4039 

Articles International conference proceedings:

53. Wannigama, D.L., Kueakulpattana, N., Luk-In, S., Hongsing, P., Hurst, C., Badavath, V.N., Jenjaroenpun, P., Wongsurawat, T., Teeratakulpisan, N., Kerr, S.J. and Abe, S., 2021, November. 1355. Cluster of Multi-drug Resistance Neisseria gonorrhoeae Isolates with Reduce Ceftriaxone Susceptibility, First Report in Thailand. In Open Forum Infectious Diseases 2021, (Vol. 8, Supplement_1, S764-S764). US: Oxford University Press. (IF: 3.83). ISSN: 2328-8957
54. Reddy, A. Sreenath, L. Sivarama Krishna, Vishnu Nayak Badavath, G. Sravya, N. Bakthavatchala Reddy, and Grigory V. Zyryanov. Synthesis, spectroscopic characterization and molecular docking studies of 2-butyl-4-chloro-5-formylimidazole thiosemicarbazone cobalt (II) complex. AIP Conference Proceedings, vol. 2063, No. 1, p. 040054. AIP Publishing, 2019. (org/10.1063/1.5087386). 

Abstracts accepted in international conference:

55. Vishnu Nayak Badavath, et al., Design, synthesis and biological screening of MAO inhibitors. Psychology, Autism and Alzheimer's disease. Sep.30-Oct. 01, 2013Hilton San Antonio Airport, TX,
56. Vishnu Nayak Badavath, et al., In Modern Synthetic Methodologies for Creating Drugs and Functional Materials (MOSM2018): 15-17 Nov. 2018, at Yekaterinburg, Russia.
57. Vishnu Nayak Badavath, et al., International Multidisciplinary Symposium on Drug Research & Development, Organized by Faculty of Anadolu University & Society of Researchers in Pharmacy and Medicine (ILARUD), Eskisehir, Turkiey. Oct 15-19,2015.

Vishnu Nayak Badavath, et al., Modern Synthetic Methodologies for the Creation of Medicines and Functional Materials (MOSM2018)-Ekaterinburg, 2019, Ural University Publishing House, Russia, 2020, 259-259

 Patents (International: 02 /National 07):

1. US Patent (USPTO): (Complete specification US Patent Appl. No.: 17/347,261). Kobophenol A for the treatment of Corona Virus 2 (SARS-CoV-2) infection, date of priority: 14^th 2021. Pub. No.: US2021/0388455 A1; Pub. Date: 16^th Dec. 2021.

Inventors/ applicant: Vishnu Nayak Badavath, Suresh Gangadevi, Na Yin, Ke wang. https://patentimages.storage.googleapis.com/30/26/c5/82de1b8c98e00c/US20210388455 A1.pdf.

2. Title: Kobophenol A for the treatment of Corona Virus 2 (SARS-CoV-2) infection (Patent No.: 202041024910, complete specification: filed on 13^th 2020. (A complete specification submitted on 11^th June 2021). Publication Date (U/S 11A) 17/12/2021. CBR: 18585. Appl. No: TEMP/E-1/27323/2020-CHE. Inventors/ applicant: Vishnu Nayak Badavath, Suresh Gangadevi, Na Yin, Ke wang. 

3. Title: Benzofuran and pyrazole substituted 1, 3, 4-oxadiazolecompounds, compositions and Process of preparation thereof (Complete specification: Patent No.: 202111036012, DATE OF FILING 10/08/2021. Publication Date (U/S 11A) 03/03/2023. CBR: Appl. TEMP/E-1/40266/2021-DEL. Inventors: Vishnu Nayak Badavath, Satish S. KOLA, Idress Mohammad, SIDDIQUI Naqui J, Sandeep Arora, Tapan Behl. 

4. Title: 2-amino-4H-pyran coupled imidazo[1,2-a]pyridine, their synthesis, anticancer activity and methods thereof (Complete specification: Patent No.: 202111040855, DATE OF FILING 09/09/2021. PUBLICATION DATE (U/S 11A) 17/03/2023. CBR: Appl. TEMP/E-1/45938/2021-DEL. Inventors: Vishnu Nayak Badavath, Rambabu Gundla, Durba Pal, Manohar Mantipally, Bhavya Kumari. 

5. Title: Pyrrolo[2,3-a] carbazole-2-carboxylatederivatives, their synthesis, anticancer activity and methods thereof. (Complete specification: Patent No.: 202111042979. DATE OF FILING 22/09/2021. PUBLICATION DATE (U/S 11A) 24/03/2023. (CBR: 33487). Appl.: TEMP/E-1/48352/2021-DEL.

Inventors: Vishnu Nayak Badavath, Saravanabhavan Munusamy, Sekar Marimuthu, GUNASEKARAN Raja, Saurabh Gupta

6. Title: 3-chlorobenzyl linked 1,9-diazaspiro[5.5]undecane derivatives, their synthesis anti Dengue virus inhibitory activity and methods thereof. (Complete specification Patent No.: 202111045712, DATE OF FILING 07/10/2021. PUBLICATION DATE (U/S 11A) 14/04/2023. CBR: 35623. TEMP/E-1/51627/2021-DEL. Inventors: Gundla Rambabu, Vishnu Nayak Badavath, Boonyasuppayakorn Siwaporn, GANGIREDDY, Madhu Sudhana Reddy. 

7. Title: A Quinoline anti-tubercular compound, compositions and process of preparation thereof. (Patent No.: 202111054540, DATE OF FILING: 25/03/2022). PUBLICATION DATE (U/S 11A). 19/05/2023. CBR: (Appl.: TEMP/E-1/61790/2021-DEL) Inventors: Sandeep Arora, Ritchu Babbar, Vishnu Nayak Badavath. 

8. Anti-cancer pyrido[2,3-a]carbazole compounds, their compositions and process of synthesis thereof. (Complete specification, Patent No.: 202111060040 (TEMP/E-1/67954/2021- DEL), Publication Date (U/S 11A) 23/06/2023 (DATE OF FILING: 22 Dec. 2021). CBR: Appl. TEMP/E-1/67954/2021-DEL. Inventors: M. Saravanabhavan, Vishnu Nayak Badavath, Shanmugam Ramesh, Sekar Marimuthu, LESHAN WANNIGAMA. 

9. A composition for management of SARS-CoV2 comprising delta-viniferin. (Provisional specification, (Patent No.: 202111059759, PUBLICATION DATE (U/S 11A). DATE OF FILING: 21^st 2021). CBR: 45626. Appl. TEMP/E-1/67817/2021-DEL. Inventors: Vishnu Nayak Badavath, Sandeep Arora, Dhammika Leshan Wannigama, Sukhbir Singh, Tapan Behl. 

Book and book chapters:

1. Chapter 6: Pharmacophore modelling in drug design in edited book Computer-Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches. 2022, Publisher: Elsevier, (ISBN: 9780323906081). Authors: Siddhartha Maji, Anik Sen, Vishnu Nayak Badavath*. 

2. Chapter 3: MAO inhibitory activity of 4, 5-dihydro-1H-pyrazole derivatives: A platform to design novel Antidepressants, Frontiers in Drug Design and Discovery, 2020, Vol. 10, 47-91, Bentham Science Publisher, Doi:2174/9789811421563121100005 (ISSN: 15740889, 22121060). Authors: Vishnu Nayak Badavath*, Venkatesan Jayaprakash. 

3. Chapter 31: Synthetic Analogues of Curcumin: The search for Anticancer and Antioxidant activities, In book Science of spices & Culinary Herbs, Vol. 6, 1-30, Bentham Science Publishers Pte. Ltd. Singapore. ISBN (eBook): 978-1-68108-751-1; (Print): 978-1-68108-752-8. Authors: Vishnu Nayak Badavath*, Siddhartha Maji, Munusamy, S., V. Jayaprakash. 

4. Chapter 6: Drug Repurposing and Computational Drug Discovery for Viral Infections and Corona Virus Disease 2019 (COVID-19). In Book: Drug Repurposing and Computational Drug DiscoveryStrategies and Advances. Siddhartha Maji, Vishnu Nayak Badavath, Swastika Ganguly. Apple Academy Press 2022. (Hard ISBN: 9781774912775). In Production. Pub Date: Forthcoming April 2023. Pages: 344pp w/ index 

5. Chapter 7: Importance of in-silico tools in anticancer drug discovery from Nature. Alternative Remedies and Natural products for Cancer Therapy: An Integrative Approach, 2021, 125-164. (Accepted Manuscript). 

AICTE-QIP Programme attended:

1. Certificate of Participation in AICTE-QIP-2012, Organized by Dept. of Pharm. Sci. & Tech. (UGC-SAP & DST-FIST Supported Dept.) Birla Institute of Technology (BIT-Mesra), Ranchi- 835215, India.
2. Certificate of participation in AICTE-QIP-2011, Organized by Dept. of Pharm. Sci. & Tech. (UGC-SAP & DST-FIST Supported Dept.) Birla Institute of Technology (BIT-Mesra), Ranchi- 835215, India.

Invited talk/Guest Speaker at International and National conference/ seminar: 04

International conference/ Webinar attended: 15

National conference/ Webinar attended: 15

Workshop attended: 10

Membership of professional Bodies

• Editorial Board Member of Journal of Drug design and Medicinal Chemistry, Science Publishing Group (Science PG), independent international publisher.
• Acting as a reviewer for various International scientific publications like (Science direct, Springer, Bentham, Wiley, etc)
• Life member of Indian Pharmaceutical Association
• Registered Pharmacist from Telangana Pharmacy council, Hyderabad-2011, India
• Completed online certified course "General Course on Intellectual Property” from WIPO-Worldwide Academy, Geneva, Switzerland. 

Tel.: +91-9430316423; E-mail: vishnu.niper@gmail.com;

ORCID: https://orcid.org/0000-0002-6433-2691

Scopus Author ID: 56463059600

https://scholar.google.co.in/citations?hl=en&user=WZM2Q8YAAAAJ